Terminated PHASE4 INTERVENTIONAL 2-arm NCT01777217

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

A Pilot Study to Assess the Safety and Efficacy of Solifenacin (VESIcare) for Improving Urinary and Bladder Functions in Patients Undergoing Radiation Therapy of the Prostate

Sponsor: Advanced Research Network

Conditions Over-Active Bladder

Interventions Placebo Solifenacin succinate

Updated 9 times since 2017 Last updated: Jan 8, 2015 Started: Feb 28, 2013 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Listed as NCT01777217, this PHASE4 trial focuses on Over-Active Bladder and remains terminated or withdrawn. Sponsored by Advanced Research Network, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE4
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE4
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE4

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Advanced Research Network
Astellas Pharma US, Inc.

Data source: Advanced Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States